Stockpolly
Search
HIND · NASDAQ · Biotechnology

Vyome (HIND)

Develops topical therapies for inflammatory conditions and cancer-wound symptoms.

$2.23
Pre-market+0.01 (+0.45%)
At close$2.22(+2.30%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue222222110000
Cost of revenue101110010000
Gross profit121111110000
543333331111
Research & development110001000011
433331221100
Selling & marketing211111100000
General & administrative222221200000
Other expenses100001000000
Operating income−4−2−2−2−2−2−2−2−1−1−1−1
0000004−1−8000
Interest income000000000000
Interest expense000000000000
Other non-operating income−10000−1018000
Income before tax−4−2−2−2−2−21−3−9−1−1−1
Income tax expense000000000000
Net income from continuing operations−4−2−2−2−2−21−3−9−1−1−1
Net income−4−2−2−2−2−21−3−8−1−1−1
EPS, basic−$1,484.16−$104.97−$135.56−$91.70−$77.67−$60.31$9.42−$9.00−$29.42−$0.21−$0.17−$0.10
EPS, diluted−$1,484.16−$104.97−$135.56−$91.70−$77.67−$60.31$9.42−$9.00−$29.42−$0.21−$0.17−$0.10
Weighted average shares, basic000000000667
Weighted average shares, diluted000000000667
EBITDA−3−2−2−2−2−1−2−3−9−1−1−1
Depreciation & amortization000000000000
EBIT−3−2−2−2−2−1−2−3−9−1−1−1